1Gravalos C,Jimeno A.HER2 in gastric cancer:a new prognostic factor and a novel therapeutic target.Ann Oncol,2008,19:1523-1529.
2Ismail HM,Moneer M,EI-Baradie M,et al.Clinicopathologic and prognostic significance of overexpression of Her-2/neu and p53 oncoproteins in gastric carcinoma using tissue microarray.J Egypt Nat Cancer Inst,2007,19:147-157.
2Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target[ J]. Ann Oncol, 2008, 19 (9) : 1523-1529.
3Sugano K, Ushiama M, Fulentomi T, et al. Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is use- ful as a sensitive tumor marker for monitoring tumor relapse[J]. Int J Cancer, 2000, 20, 89(4) : 329-336.
4Moreno A, Lloveras B, Figrueras A, et al. Ductal carcinoma in situ of the breast: correlation between histologic classification and biological markers[J]. Mod Pathol, 1991, 10( 11 ): 1088-1089.
5Mack L, Kerkvliet N, Doig G, et al. Relationship of a new histo- logical categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical espression of p53, c-erbB2, bcl-2, and ki-67[J]. Hum Pathol. 1997, 28(8) : 974-979.
6Oya M, Yao T, Tsuneyoshi M. Expressions of cell cycle regulatory- gene products in conventional gastric adenomas: possible immuno- histochemical markers of malignant transformation [ J ]. Hum Pathol, 2000, 31(3): 279-287.
7Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase II a gene am- plification, intestinal type, poor prognosis and sensitivity to trastu- zumab[J]. Ann Oncol, 2005, 16(2): 273-278.
8Matsui Y, Inomata M, Tojigamori M, et al. Snppression of tumor growth in human gastric cancer with HER2 overexpression by an an- ti-HER2 antibody in a murine model[J]. Int J Oncol, 2005, 27 (3) : 681-685.
9Fujimoto-Ouchi K, Sekiguehi F, Yasuno H, et al. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models[ J]. Cancer Chemother Pharmacol, 2007, 59(6) : 795-805.
10Corte's-Funes H, Rivera F, Ale' s I, et al. Phase lI of trastu- zumab and cisplatin in patients with advanced gastric cancer with HER2/neu overexpression/amplification[ J]. J Clin Oncol, 2007, 15(5) : 113-115.
